PE20030920A1 - Formas cristalinas de agonistas del receptor b3-adrenergico, procedimiento para su preparacion y sus usos - Google Patents

Formas cristalinas de agonistas del receptor b3-adrenergico, procedimiento para su preparacion y sus usos

Info

Publication number
PE20030920A1
PE20030920A1 PE2003000194A PE2003000194A PE20030920A1 PE 20030920 A1 PE20030920 A1 PE 20030920A1 PE 2003000194 A PE2003000194 A PE 2003000194A PE 2003000194 A PE2003000194 A PE 2003000194A PE 20030920 A1 PE20030920 A1 PE 20030920A1
Authority
PE
Peru
Prior art keywords
procedure
preparation
refers
diffraction
agonists
Prior art date
Application number
PE2003000194A
Other languages
English (en)
Inventor
Jennifer Anne Lafontaine
Joseph Francis Krzyzaniak
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030920A1 publication Critical patent/PE20030920A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DE LA SAL DE p-TOLUENSULFONATO DEL (R)-2-(2-(4-OXAZOL-4-IL-FENOXI)-ETILAMINO)-1-PIRIDIN-3-IL-ETANOL QUE PRESENTA PICOS DE DIFRACCION DE RAYOS X DE ALTA INTENSIDAD A ANGULOS DE DIFRACCION (2 THETA) DE 6,0 Y 18,1 Y DISTANCIA (d) DE DIFRACCION DE RAYOS X DE POLVO DE 14,7 Y 4,9 RESPECTIVAMENTE. LA FORMA CRISTALINA TIENEN UNA TEMPERATURA DE FUSION DE 160°C. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE PREPARAR UNA SOLUCION DE (R)-2-(2-(4-OXAZOL-4-IL-FENOXI)-ETILAMINO)-1-PIRIDIN-3-IL-ETANOL EN UN SOLVENTE INERTE PARA LA REACCION Y TRATAR DICHA SOLUCION CON ACIDO p-TOLUENSULFONICO MONOHIDRATO PARA OBTENER UNA RELACION ESTEQUIOMETRIA AL FINAL DE 1:1. EL PROCEDIMIENTO SE LLEVA A CABO EN UN SOLVENTE INERTE COMO TETRAHIDROFURANO. SE REFIERE TAMBIEN A METODOS PARA TRATAR LA DIABETES Y LA HIPOGLUCEMIA CON DICHAS FORMAS CRISTALINAS
PE2003000194A 2002-02-27 2003-02-27 Formas cristalinas de agonistas del receptor b3-adrenergico, procedimiento para su preparacion y sus usos PE20030920A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36025202P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
PE20030920A1 true PE20030920A1 (es) 2003-10-29

Family

ID=27766208

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000194A PE20030920A1 (es) 2002-02-27 2003-02-27 Formas cristalinas de agonistas del receptor b3-adrenergico, procedimiento para su preparacion y sus usos

Country Status (8)

Country Link
US (2) US6689800B2 (es)
AU (1) AU2003209527A1 (es)
GT (1) GT200300042A (es)
PA (1) PA8567501A1 (es)
PE (1) PE20030920A1 (es)
TW (1) TW200400962A (es)
UY (1) UY27677A1 (es)
WO (1) WO2003072573A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
US8377465B2 (en) 2005-02-11 2013-02-19 Kansas State University Research Foundation Product and process for elevating lipid blood levels in livestock
EP4161496A1 (en) * 2020-06-04 2023-04-12 Curasen Therapeutics, Inc. Forms and compositions of a beta adrenergic agonist

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
US5051423A (en) 1988-07-13 1991-09-24 Schering Ag Derivatized alkanolamines as cardiovascular agents
US5030640A (en) 1989-01-05 1991-07-09 Merck & Co., Inc. Novel β-adrenergic agonists and pharmaceutical compositions thereof
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
ATE154935T1 (de) * 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
CN1079794C (zh) 1994-04-08 2002-02-27 住友化学工业株式会社 醚类化合物,它们的应用以及其制备中所用的中间体
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
CA2220399A1 (en) 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
TR199800521T1 (xx) 1995-09-21 1998-06-22 Eli Lilly And Company Se�imli beta3 adrenerjik agonistler.
EP0882707B1 (en) 1996-01-10 2003-10-08 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US6008361A (en) 1996-04-09 1999-12-28 Pfizer Inc. Substituted pyridines
US5859044A (en) 1996-07-31 1999-01-12 Pfizer Inc. β-adrenergic agonists
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
TR199901063T2 (xx) 1996-11-14 1999-08-23 Pfizer Inc. �kame edilmi� piridinler i�in i�lem.
US6001856A (en) 1997-06-13 1999-12-14 Pfizer Inc. β-adrenergic agonists to reduce a wasting condition
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6090942A (en) 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
DE60015036T2 (de) 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
US6451587B1 (en) 1999-09-29 2002-09-17 Pfizer Inc. Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
BR0114836A (pt) * 2000-10-20 2003-07-01 Pfizer Prod Inc Agonistas de receptores beta-3 adrenérgicos e suas aplicações
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol

Also Published As

Publication number Publication date
US20030199556A1 (en) 2003-10-23
AU2003209527A1 (en) 2003-09-09
GT200300042A (es) 2003-09-22
PA8567501A1 (es) 2003-11-12
US20030166686A1 (en) 2003-09-04
TW200400962A (en) 2004-01-16
US6689800B2 (en) 2004-02-10
UY27677A1 (es) 2003-10-31
WO2003072573A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
PA8645701A1 (es) Procedimiento para producir derivados de amina opticamente activos
AR068527A2 (es) Un procedimiento para preparar monohidrato de bromuro de tiotropio cristalino
PE20000056A1 (es) Teriparatida cristalina
ES2543804T3 (es) Polimorfo B de Ibandronato
PE20081258A1 (es) ANTICUERPOS ANTI-hTNFALFA CRISTALINOS
AR067775A1 (es) (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso
WO2009028530A1 (ja) チタン酸化合物及びその製造方法並びに該チタン酸化合物を含む電極活物質、該電極活物質を用いてなる蓄電デバイス
ECSP10010719A (es) Una nueva sal de glicinato de metformina para el control de la glucosa en sangre
PE20061310A1 (es) Forma cristalina de la sal clorhidrato de 1-isopropil-2-oxo-1,2-dihidroquinolina-3-acido carboxilico {(1s,3r,5r)-8-[(r)-2-hidroxi-3-(metanosulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida
NZ590288A (en) Topical composition for the treatment of actinic keratosis containing less than 5 per cent water
PE20030920A1 (es) Formas cristalinas de agonistas del receptor b3-adrenergico, procedimiento para su preparacion y sus usos
CO6190527A2 (es) Moduladores de la actividad del receptor de quimiocina formas cristalinas y procesos
CO2022015927A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
ES2649740T3 (es) Método simple para la preparación de 5-nitrotetrazolatos usando un sistema de flujo
PE20060720A1 (es) Procedimiento para fabricar r-(-)-sertaconazol mononitrato
CO6270318A2 (es) Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465
PE20060170A1 (es) Nueva forma cristalina de acido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo[4.3.0]nonan-8-il)-6-fluoro-1,4-dihidro-4-oxo-3-quinolincarboxilico
Shalini et al. Assessing the role of light absorption in laser lithotripsy by isotopic substitution of kidney stone materials
CO6120151A1 (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina
RU2008109958A (ru) Кристаллические соли 7-[4-(4-нафталин-1-илпиперазин-1-ил)бутокси]-3, 4-дигидро-1н-[1, 8]нафтиридин-2-она
PE20081167A1 (es) Sal de alisquireno
EA200800861A1 (ru) Способ получения четвертичных аммониевых солей с кислотой
Prasanyaa et al. Synthesis, characterization and anti-microbial activity of pure, Cu2+ and Cd2+ doped organic NLO l-arginine trifluoroacetate single crystals
PE20070368A1 (es) Sal maleato del compuesto 3-[2-(dimetilamino)metil-(ciclohexil)]-fenol y sus formas cristalinas
Thippeshappa et al. Effect of biocompatible nucleants in rapid crystallization of natural amino acids using a CW Nd: YAG laser

Legal Events

Date Code Title Description
FD Application declared void or lapsed